Premium
CD44/CD24 expression on salivary glands malignant neoplasms (SGMN)
Author(s) -
Soave Danilo Figueiredo,
Costa João Paulo Oliveira,
Silveira Giorgia Gobbi,
Ianez Renata Carolina Fraga,
Oliveira Lucinei Roberto,
Lourenço Silvia Vanessa,
Silva Alfredo Ribeiro
Publication year - 2013
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.27.1_supplement.lb456
Subject(s) - cd24 , cd44 , lymph node , medicine , immunohistochemistry , stage (stratigraphy) , pathology , oncology , cancer research , cancer , biology , cell , cancer stem cell , genetics , paleontology
Background CD44 is the binding site for hyaluronic acid, and CD24 is a receptor that interacts with P‐selectin to induce tumor progression. Present study aims to evaluate CD44/CD24 expression on SGMNs and correlated these data with clinicopathologic features. Methods Immunohistochemical stains for CD44/CD24 were performed on 69 SGMN samples. CD44/CD24 expression was correlated to patient clinicopathologic features and outcome. Results CD44 expression was associated with the primary site of neoplasm (p=0.046). CD24 was associated with clinical stage III/IV (p=0.008), T stage (p=0,27) and lymph node (p=0,001). The CD44/CD24 profiles were associated with the primary site of injury (p=0.005), lymph node (p=0.011) and T stage (p=0.023). Conclusion in summary, we have presented some evidence that the analysis of CD44/CD24 expression could give prognostic information associated to clinicopathologic features in SGMN.